TigonTalker

@Theta_Ron @AnaniBeaumont 😎

Nice snipe @AnaniBeaumont 👍 $theta #edgecloud #AI #compute

@ThrillaRilla369 Bo Jackson

Age yourself by naming an NFL player from your childhood. I'll start: Dan Marino

@lovemesometfue1 @MagnumPine @Thetafund @Theta_Network Chances are they never read the white papers

It’s called optimism, enthusiasm, and ambitions. Everyone with half a brain understands that this market is dynamic and moves extremely fast. Every adoption and "realignments" Theta has full support by 99% of the community and the project has never looked better. You and your friend have tainted 2 beautiful pineapples. Do you think Thomas Magnum would have acted like a little baby about this like you are and be simping over the dog blog girl? Shocking..

Final boss energy from @Theta_Network's May 2025 AMA: "We have announcements every week going into July." "We possibly have too many deals." Too. Many. Deals. Name another project with this problem. I'll wait. $THETA 🚀

$NWBO AstraZeneca is conducting a Phase 2 multi-site trial, TRAVERSE, in patients with treatment-naïve mantle cell lymphoma, with participation from The University of Texas MD Anderson Cancer Center and University of Pennsylvania. A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse) clinicaltrials.gov/study/NCT05951… Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study ashpublications.org/blood/article/…

@Biostruck7 @andrewcaravello 💯

@andrewcaravello Very true. Most docs I’ve spoken with don’t know

🩺 Most of the people you’re trying to convince about $NWBO #DCVax have never heard of a dendritic cell. ⚠️ That’s the problem. You can’t ask someone to care about a Phase 3 trial, a compassionate-use pathway, or a regulatory decision when they don’t yet understand what the therapy actually does, why the immune system needs it, or why some patients run out of time before the foundations alone can fix what’s broken. 📖 The Biological Reboot was written, in part, to close that gap. 🧬 The book is an explainer. It walks the reader through the cell at the center of immune surveillance, the cDC1 dendritic cell, and the master gene inside it that decides whether your immune system can recognize and clear a tumor, a senescent cell, a latent infection. That gene is IRF8. When IRF8 is expressing, your dendritic cells produce IL-12, the instruction signal that tells your T cells what to attack and what to leave alone. When IRF8 is silenced by decades of low-grade inflammation, by SASP signals from senescent cells, by the cascade the book maps in detail, IL-12 falls. The instruction stops. Cancer slips through. Latent infections reactivate. Damaged cells stop being cleared. 🛑 This is why some cancers progress even when immunotherapy is on board. Checkpoint inhibitors release the brakes on T cells. They do not give those T cells anything to recognize. If the upstream instructor cell has been silenced, releasing the brakes does not restore the instruction. The T cell becomes free to act, but it does not know what to act on. The framework explains why that approach hits a wall in the patients it hits a wall in, and why the missing piece is upstream, not downstream. 🔬 The book then shows you, mechanistically, how to keep IRF8 active in your own body. Vitamin C activates the enzyme that erases the silencing marks. Sleep preserves the circadian peak that drives the IL-12 monocyte. Exercise produces the pulsatile IL-6 signature your immune system reads as health. Matcha and coffee inhibit the enzyme that installs the silencing in the first place. Social connection downregulates the inflammatory transcription factor at the top of the cascade. Eight inputs, mapped to eleven molecular locks, with evidence tiers for every claim. ⏳ That is what the book teaches the reader to do for themselves, while there is still time. ⚖️ But the book also names, plainly, the limit of what foundations can accomplish. 🎯 Foundations until you can’t. Then the cell. 🧱 Once enough dendritic cell progenitors have crossed the irreversible epigenetic threshold, what the book calls Switch 2, lifestyle alone cannot fully restore the instruction. The silencing is locked in. The factory is producing the wrong outputs. At that point, the only path that remains is to deliver dendritic cells that were manufactured outside the silencing field, with their IRF8 intact, ready to issue the IL-12 instruction the patient’s own cells can no longer give. 🧫 Chapter 21 of the book covers this in full. The cell is the alpha-DC1, the same cell NWBO has licensed and is delivering through the DCVax platform. The bioreactor matters because the cell has to be matured in a clean environment, free of the SASP signals that would silence it the moment it tried to instruct. That is why endogenous rescue cannot work past a certain point. The patient’s own bone marrow is the silencing field. You cannot manufacture a working instructor inside a factory whose machinery has been turned against the product. You manufacture it outside, then return it. 💉 The book teaches your dendritic cells how to do their job. The alpha-DC1, manufactured ex vivo, does the job for the patients who can no longer wait. 📊 DCVax-L for glioblastoma. DCVax-Direct for solid tumors. DCVax-Prostate for hormone-independent prostate cancer. The Phase 3 glioblastoma data crossed the trial sequential analysis benefit boundary in a meta-analysis of 3,619 patients. Compassionate-use pathways exist, in specific jurisdictions, for patients who qualify. 👨‍👩‍👧 If you have a family member who keeps asking why you care so much about a small biotech company, why you post about #DCvaxForBraelyn, why a Phase 3 trial in glioblastoma matters for someone they love, buy them this book. By the end of it they will understand the cell, the gene, the cascade, the foundations, and the bioreactor. They will close it knowing why the manufactured version exists, why some patients need it now rather than years from now, and why the science behind it is the same science that explains why their own father is aging the way he is. 🤝 This is the book to put in your father’s hands. Your sister’s. The skeptical friend who thinks immunotherapy is a buzzword. They will close it knowing what a dendritic cell is, what IL-12 does, why IRF8 silencing is the upstream failure, and why the patients fighting for DCVax access are fighting for a therapy that addresses the actual mechanism. Not a workaround. Not a Hail Mary. The missing piece. ❤️ Braelyn is why we are here. The book is one tool. There are others. Whatever any of us can do to get the word out, we do. 📖 The Biological Reboot a.co/d/07qU9qNy #DCvaxForBraelyn #NWBO #DCVax #Glioblastoma #Immunotherapy #DendriticCells #IL12 #IRF8 #AlphaDC1 #Bioreactor #Longevity #Immunology

Well Mrs Lambroza didn't make it quiet one year with Citadel. As of today she quit.

$NWBO @DrOz @BossBlunts1 @SecKennedy @stoolpresidente @DrMakaryFDA @MHRAgovuk @elonmusk @kshaughnessy2 Just to remind the over paid government agencies in the UK and USA .. 542 people per day die as we await the approval of DCVAX.. for Glioblastoma… 🧠 cancer for the uninitiated. You guys take your time.. 542 souls per day..TikTok Can’t make it up… Call Elon he can tell how to instill a sense of urgency in the process… Dr M stop telling us how great you are Let’s see results. 542…

$NWBO #DCVax @DrMakaryFDA

$NWBO From LP at 2025 ASM And just one last thing to remind you on that: Northwest already has a history itself in ovarian cancer. You may remember that we did a small pilot trial with DCVax-L in ovarian cancer, and it was quite strikingly encouraging at the time. We could only do the small pilot, but the academic collaborators we did that trial with many years ago, who were at Penn, and Penn has a center of excellence in ovarian cancer, they did go onwards and treat some more patients beyond what we could do, and they continued to get good results, and those results have been published. The following are the DC vaccine trials connected to Penn. Search the publications related the trials and see if some of them produced amazing results. Pay attention to how DC vaccines were manufactured, especially the maturation cocktails adopted in producing the vaccines. A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer clinicaltrials.gov/study/NCT00683… HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant) clinicaltrials.gov/study/NCT02063… DC Vaccine in Pancreatic Cancer clinicaltrials.gov/study/NCT03592… Dendritic Cell Vaccination in Patients With Advanced Melanoma clinicaltrials.gov/study/NCT03092… Pilot Trial of HER-2/​Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer clinicaltrials.gov/study/NCT02473… Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma clinicaltrials.gov/study/NCT00683… Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients (DC-Ova) clinicaltrials.gov/study/NCT00478… DC Vaccine in Colorectal Cancer clinicaltrials.gov/study/NCT03730… DC Vaccine for Patients With Ductal Carcinoma In Situ (DCIS6) clinicaltrials.gov/study/NCT02061… Autologous OC-DC Vaccine in Ovarian Cancer clinicaltrials.gov/study/NCT01132… Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast clinicaltrials.gov/study/NCT00107…

$NWBO Pexidartinib, as a CSF1R inhibitor, only brought Daiichi Sankyo $37 million in 2023 after FDA 2019 approval. I suppose those companies that own CSF1R inhibitors do know that their CSF1 inhibitors can overcome immunosuppression due to tumor-associated macrophages.

$NWBO #DCVaxForBraelyn

$NWBO Here are the trials which had DC vaccine in combination pneumococcal vaccines. It's interesting no results from those trials were published?! Maybe the results could be useful for negotiating good deals! A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer clinicaltrials.gov/study/NCT00683… Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer clinicaltrials.gov/study/NCT03942… Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma clinicaltrials.gov/study/NCT03325… Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma clinicaltrials.gov/study/NCT03035… Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma clinicaltrials.gov/study/NCT01239…

Illinois Tech joins Stanford, Imperial College London, Peking University, KAIST, Seoul National University, NTU Singapore and 27 others running research on EdgeCloud. More to come. 🤝 Read about it here: medium.com/theta-network/…

Professor Yong Zheng's lab at @illinoistech is now using Theta EdgeCloud for research in personalization, recommender systems, and human-centric AI. Our 33rd university.🧵

@Theta_Network 🚨🚨🚨🚨🚨🚨🚨🚨 medium.com/theta-network/…

@andrewcaravello Ordered mine!

🦾 What Men’s Health Almost Said About Aging One pipe. Four leaks. Men’s Health just published the right answer to the wrong question. The article profiles three athletes — Chris Paul at 40, Bill Maeda at 57, Robert Plant at 82 — who have stayed fast, strong, and durable into ages where their peers have given up. The advice is good. The science it cites is real. But the piece stops one layer above the actual biology, and that layer is what changes everything. Here is what Men’s Health observes — and what the framework underneath it explains. 🦴 Grip strength predicts diabetes, cardiovascular disease, frailty, and cancer. Men’s Health cites a 2024 Italian study showing weak grip correlates with all four. It does not ask why. The framework answers: all four diseases are downstream of the same upstream failure — the silencing of IRF8 in dendritic cell progenitors, which collapses IL-12 production, which collapses immune instruction across every tissue. Your grip strength is not measuring your forearms. It is measuring whether the instructor cells in your bone marrow are still issuing orders. 📉 We lose 3–8% of muscle mass per decade. Strength at twice that rate. Power most precipitously. The article calls this inevitable but slowable. The framework calls it actively maintained. Sarcopenia is not entropy. It is the consequence of bone marrow shifting toward the wrong cellular outputs once SASP signals exceed a threshold. Chapter 25 of The Biological Reboot names this directly: the factory fires first. 🫀 Long-duration cardio is insufficient to guard against age-related strength loss. The article reports the empirical finding. The framework adds the mechanism. Slow steady cardio shifts STAT3 toward its protective mitochondrial pool. Resistance training and explosive movement engage AMPK pulses, NAD+ elevation, and the bone marrow niche protection that pure aerobic work doesn’t reach. Both matter. Neither is sufficient alone. Robert Plant returned to strength training after the pandemic for a reason. ⚡ Power loss is the first thing to go and the most important to fight for. The article cites fall prevention and everyday function. The framework adds the deeper reason. Power output depends on fast-twitch fibers, and fast-twitch fibers are governed by the same calibration system that governs autonomic balance, immune surveillance, and cognitive responsiveness. Chapter 27 makes the case directly: dysautonomia, immune dysfunction, and motor decline are not three separate problems showing up together. They are one problem expressing itself in three places. 📊 HRV reflects nervous system stress and indicates training readiness. The article gets the surface. The framework completes it. HRV reflects vagal tone. Vagal tone gates α7 nicotinic receptor activation on immune cells, which suppresses NF-κB and preserves the IL-12 instruction signal. When your wearable shows HRV declining four days before you get sick, what you are watching is the upstream cascade activating. A patient I’ll call Marcus walked into my office at 49 with a printout from his smartwatch. He had been wearing it for eight months. Six respiratory infections that year. He had predicted five of them from his wrist before any symptoms appeared. His doctors treated each infection separately. None of them asked why his immune system was failing to stop pathogens it should have been clearing. None of them measured the upstream failure. The wearable already knew. 🦶 Foot, ankle, and hip mobility as the foundation of durability. Chris Paul’s quote is true at the structural level — foundation matters. There is a deeper biology. Tissue mobility depends on local immune instruction governing inflammation clearance and tissue regeneration. Tight quads in a 40-year-old can reflect more than a flexibility deficit. The framework predicts that the dendritic cells in chronically inflamed muscle tissue are part of why the tissue stops mobilizing the way it once did. Stretching helps. Restoring instruction helps more. Chapter 30.5 covers the universal recovery architecture that explains why surgical recovery, infection clearance, and tissue regeneration all run through the same upstream pipe. 🤝 Social connection — sports, competition, community — guards against decline. The article frames this as guarding against loneliness. The framework calls it a molecular intervention. Steve Cole’s CTRA work, cited in Chapter 34, shows that loneliness directly downregulates IRF transcription factor activity and upregulates NF-κB in human immune cells. Same cells. Same chain. The “be social” advice is right. The reason it works is not psychological. It is upstream of every supplement in any longevity stack. 🧬 Slow steady aerobic work is “the real fountain of youth.” The article frames this as injury prevention. The framework reframes it as the molecular distinction between pulsatile IL-6 (released during exercise, anti-inflammatory through SOCS3) and chronic SASP-IL-6 (released by senescent cells, drives the cascade). Same molecule. Opposite biology. Source and duration determine outcome. Chapter 7 calls this the source-redistribution principle, and it resolves the apparent paradox that exercise causes massive IL-6 spikes yet extends lifespan. 🦴 Lifelong cross-country skiers in their 80s and 90s have the cardiovascular fitness of college students. The article reports this and moves on. The framework calls it the centenarian signature, and it is the most important sentence in the entire piece. People who reach extreme age with preserved function are not aging slower. They are not aging differently. They are aging through the first transition without crossing the second. Their bone marrow stays operational. Their dendritic cells stay instructional. Their IL-12 output stays high enough that the autoactivation circuit never falls below the threshold required to keep the manufacturing line running. Robert Plant has 20 national championships. He set an Ironman World Championship course record that has stood for eight years. He competes in his ninth decade. He is not exceptional because of the genetics he was born with. He is exceptional because he kept the inputs in the right state for sixty years. The framework says you do not have to start at 22 to do this. You have to start now. Chris Paul, at 40, plays a contact sport at the elite level after multiple injuries. His training emphasizes mobility, stretching, and form. Above all, he listens to his body. That is the practice the framework names as fundamental. Not the supplement stack. Not the longevity protocol. The reading of the signal your own biology is giving you. Bill Maeda beat colon cancer and trains in his late fifties with the precision of a much younger athlete. He emphasizes leg strength, hip strength, and back strength — the lower-body emphasis that the framework predicts protects against the bone marrow niche failure most likely to trigger Switch 2 in the sixth decade. These three athletes do not know about IRF8. They do not need to. They have stumbled onto, refined, and disciplined the practice that protects the upstream mechanism whether or not they can name it. The Biological Reboot is the explanation underneath what they are already doing — and the framework that lets the rest of us do it earlier, more deliberately, and with the full understanding of what each input is actually accomplishing at the molecular level. The Men’s Health article ends with this line: “Just get to the next turnaround, the next hill. I don’t even think about age. It’s not part of my game plan.” The framework agrees. Age is not the variable. The cascade is. You are not aging. You are being silenced. And silencing is reversible. 📖 The Biological Reboot — full framework, all 35 chapters, every intervention mapped to a specific molecular node: a.co/d/07qU9qNy 📰 The Men’s Health profile that motivated this thread: apple.news/AiaAnAbH4S0y2Z… #DCvaxForBraelyn #IL12 #Longevity #Immunology #Aging #DendriticCells #Healthspan #MensHealth #Sarcopenia #GripStrength #HRV #IRF8 #Centenarians

$NWBO Would Merck have been able to make strategic investment of $40b if the results from the following trials had become known to the public?! Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Principal Investigator: Timothy F Cloughesy, UCLA/Jonsson Comprehensive Cancer Center clinicaltrials.gov/study/NCT04201… openpaymentsdata.cms.gov/payment/2024/r… Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Principal Investigator: Yi Lin, MD, PhD,Mayo Clinic clinicaltrials.gov/study/NCT03035… openpaymentsdata.cms.gov/payment/2020/r… Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE) Principal Investigator: Matthew S. Block, MD, PhD,Mayo Clinic in Rochester clinicaltrials.gov/study/NCT05920… openpaymentsdata.cms.gov/payment/2024/r… Personalized DC Vaccines in Non Small Cell Lung Cancer Dr Hasna Bouchaab, Centre Hospitalier Universitaire Vaudois (Responsible Party) clinicaltrials.gov/study/NCT05195… pmc.ncbi.nlm.nih.gov/articles/PMC11… Hasna Bouchaab Honoraria: MSD Oncology (Inst), Roche (Inst), AstraZeneca (Inst), Sanofi (Inst), Janssen Oncology (Inst), PharmaMar (Inst), Amgen (Inst), Amgen (Inst), Merck (Inst), Pfizer (Inst), Bristol Myers Squibb Foundation (Inst), Takeda (Inst) Consulting or Advisory Role: Amgen (Inst), MSD Oncology (Inst), Takeda (Inst), Bristol Myers Squibb Foundation (Inst), Roche (Inst), AstraZeneca (Inst), PharmaMar (Inst), Sanofi (Inst), Janssen Oncology (Inst), Merck (Inst) Travel, Accommodations, Expenses: Amgen (Inst), AstraZeneca (Inst), PharmaMar (Inst), Janssen Oncology (Inst), Takeda (Inst) Dendritic Cell Vaccines Against Her2/​Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Principal Investigator: Shipra Gandhi, Roswell Park Cancer Institute clinicaltrials.gov/study/NCT04348… openpaymentsdata.cms.gov/payment/2024/r… Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma Principal Investigator: Matthew S. Block, M.D., Ph.D.,Mayo Clinic clinicaltrials.gov/study/NCT03325… Dendritic Cell Vaccination in Patients With Advanced Melanoma Principal Investigator: Gerald P Linette, MD, PhD,University of Pennsylvania clinicaltrials.gov/study/NCT03092… Linette served as a site investigator in Merck's landmark pembrolizumab (Keytruda) trials in advanced melanoma. The KEYNOTE program is Merck's flagship clinical development program, and Linette's participation as an enrolling investigator constitutes a direct research relationship with Merck.